Cancer Research Cancer Epigenetics  Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Published online first on January 20, 2009
[Cancer Research, 10.1158/0008-5472.CAN-08-2806]
This Article
Right arrow Full Text (Online First [PDF])
Right arrow All Versions of this Article:
0008-5472.CAN-08-2806v1
69/3/1150    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schild-Hay, L. J.
Right arrow Articles by Poirier, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schild-Hay, L. J.
Right arrow Articles by Poirier, M. C.

Prevention

Tamoxifen Induces Expression of Immune Response–Related Genes in Cultured Normal Human Mammary Epithelial Cells

Laura J. Schild-Hay 1, Tarek A. Leil , Rao L. Divi , Ofelia A. Olivero , Ainsley Weston , Miriam C. Poirier *

1 1Carcinogen-DNA Interactions Section, LCBG, CCR, National Cancer Institute, NIH, Bethesda, Maryland; 2Division of Respiratory Disease Studies, National Institute for Occupational Safety and Health, CDC, Morgantown, West Virginia; 3Bristol-Meyers Squibb, Discovery Medicine and Clinical Pharmacology, Pennington, New Jersey; and 4PPD, Richmond, Virginia

* To whom correspondence should be addressed. E-mail: poirierm{at}exchange.nih.gov.


   Abstract

Use of tamoxifen is associated with a 50% reduction in breast cancer incidence and an increase in endometrial cancer incidence. Here, we documented tamoxifen-induced gene expression changes in cultured normal human mammary epithelial cells (strains 5, 16, and 40), established from tissue taken at reduction mammoplasty from three individuals. Cells exposed to 0, 10, or 50 µmol/L of tamoxifen for 48 hours were evaluated for (E)-{alpha}-(deoxyguanosine-N2-yl)-tamoxifen (dG-N2-TAM) adduct formation using TAM-DNA (DNA modified with dG-N2-TAM) chemiluminescence immunoassay, gene expression changes using National Cancer Institute DNA-oligonucleotide microarray, and real-time PCR. At 48 hours, cells exposed to 10 and 50 µmol/L of tamoxifen were 85.6% and 48.4% viable, respectively, and there were no measurable dG-N2-TAM adducts. For microarrays, cells were exposed to 10 µmol/L of tamoxifen and genes with expression changes of >3-fold were as follows: 13 genes up-regulated and 1 down-regulated for strain 16; 17 genes up-regulated for strain 5, and 11 genes up-regulated for strain 40. Interferon-inducible genes (IFITM1, IFIT1, MXI, and GIP3), and a potassium ion channel (KCNJ1) were up-regulated in all three strains. No significant expression changes were found for genes related to estrogen or xenobiotic metabolism. Real-time PCR revealed the up-regulation of IFNA1 and confirmed the tamoxifen-induced up-regulation of the five other genes identified by microarray, with the exception of GIP3 and MX1, which were not up-regulated in strain 40. Induction of IFN-related genes in the three normal human mammary epithelial cell strains suggests that, in addition to hormonal effects, tamoxifen exposure may enhance immune response in normal breast tissue. [Cancer Res 2009;69(3):1150–5]

Key Words: microarray, RT-PCR, TAM-DNA chemiluminescence immunoassay, IFN







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2009 by the American Association for Cancer Research.